Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Celularity Inc.NASDAQ: CELU

Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025

Depreciation & amortization declines year over year

Q4 FY2025 depreciation & amortization of $1.8M fell 3.9% year over year, ahead of the -7.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.4% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.

Context

  • Depreciation & amortization amounted to 27.5% of revenue in FY2025, up 12.9 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -3.9% holds above the trailing-twelve-month pace of -7.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.8M-3.4% QoQ
Last fiscal yearDec 2025
$7.3M-7.9% YoY
LTMDec 2025
$7.34M-7.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.9%——
1 year-7.9%——
3-year CAGR-8.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
7.3M USD
Year-over-year change
-7.9%
4-year CAGR
-4.6%

Depreciation & Amortization vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 depreciation & amortization of $7.34M is the highest of the 4 companies compared; the peer median is $405.5K.
  • Its year-over-year change of -7.4% is the 2nd highest of 3, against a peer median of -8.9%.
  • Depreciation & amortization amounts to 27.6% of revenue for CELU, versus a peer median of 2.5%.
CELU Competitors Peer median
Depreciation & Amortization for CELU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$7.34M -7.4%-8.2%27.6%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$873K +7.1%+5.5%2.5%
PYPDPolyPid Ltd.LTM Mar 2026$405.5K —-2.0%—
ANVSAnnovis Bio, Inc.LTM Mar 2026$3 -25.0%——
Peer median (excluding CELU) $405.5K-8.9%+1.8%2.5%

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.34M17.98M22.77M54.22M26.55M
Cost of Revenue9.65M19.67M16.02M14.99M6.36M
Gross Profit11.68M(1.69M)6.76M39.23M20.19M
Gross Margin54.8%-9.4%29.7%72.4%76.0%
Research & Development88.35M78.36M30.47M17.39M15.03M
Selling, General & Admin71.34M66.02M50.58M58.64M51.27M
Operating Expenses120.74M23.91M199.04M77.59M81.5M
Depreciation & Amortization8.82M9.44M9.32M7.92M7.3M
EBITDA(88.11M)(138.83M)(183.95M)(43.71M)(77.66M)
EBITDA Margin-413.0%-772.4%-807.8%-80.6%-292.5%
Operating Income(109.06M)(25.6M)(192.29M)(38.36M)(61.31M)
Operating Margin-511.2%-142.4%-844.4%-70.7%-230.9%
Interest Income332K365K320K331K262K
Interest Expense3.17M03.02M6.26M6.75M
Other Income / Expenses8.96M39.81M(4M)(19.53M)(30.41M)
Income Before Tax(100.1M)14.21M(196.29M)(57.89M)(91.71M)
Pre-Tax Margin-469.2%79.0%-862.0%-106.8%-345.4%
Income Tax Expense20K13K10K03K
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.8M)
Net Margin-469.3%79.0%-862.0%-106.8%-345.8%
EPS (Basic)(7.87)1.01(11.02)(2.64)(3.59)
EPS (Diluted)(7.87)0.95(11.02)(2.64)(3.59)
Weighted Avg Shares12.73M13.99M17.81M21.89M25.6M
Weighted Avg Shares (Diluted)12.73M14.98M17.81M21.89M25.6M

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.